Research Article
Lysophosphatidic Acid Analogue rather than Lysophosphatidic Acid Promoted the Bone Formation In Vivo
Table 1
Whole blood cell analysis of mice after treatment with LPA or analogues.
| | Index | Control | LPA | Analogues |
| | WBC (×109/L) | 6.33 ± 1.57 | 6.33 ± 2.01 | 6.27 ± 1.81 | | Lymph (×109/L) | 1.85 ± 0.28 | 1.80 ± 0.22 | 1.87 ± 0.24 | | Mon (×109/L) | 0.35 ± 0.19 | 0.30 ± 0.14 | 0.30 ± 0.14 | | Gran (×109/L) | 3.26 ± 0.52 | 3.16 ± 1.01 | 2.90 ± 0.16 | | Lymph (%) | 34.47 ± 8.91 | 38.20 ± 9.38 | 33.70 ± 2.21 | | Mon (%) | 4.98 ± 0.84 | 4.73 ± 1.06 | 4.97 ± 0.19 | | Gran (%) | 59.62 ± 7.60 | 56.73 ± 10.10 | 59.33 ± 3.45 | | RBC (×1012/L) | 8.98 ± 0.52 | 9.04 ± 0.53 | 9.09 ± 0.30 | | HGB (g/L) | 141.00 ± 5.81 | 137.00 ± 2.16 | 143.67 ± 9.53 | | HCT (%) | 46.13 ± 3.23 | 41.73 ± 8.06 | 46.63 ± 4.69 | | MCV (fL) | 48.27 ± 3.93 | 48.67 ± 0.45 | 46.50 ± 4.81 | | MCH (pg) | 15.57 ± 2.25 | 15.77 ± 1.51 | 15.20 ± 0.78 | | MCHC (g/L) | 316.30 ± 5.80 | 303.30 ± 21.10 | 314.33 ± 2.36 | | RDW (%) | 15.87 ± 2.81 | 15.57 ± 2.25 | 15.17 ± 0.57 | | PLT (×109/L) | 809.67 ± 80.5 | 767.33 ± 51.65 | 836.67 ± 226.18 | | MPV (fL) | 5.52 ± 0.82 | 5.97 ± 0.70 | 5.83 ± 0.21 | | PDW | 17.53 ± 0.35 | 17.43 ± 0.33 | 17.50 ± 0.22 | | PCT (%) | 0.38 ± 0.17 | 0.39 ± 0.11 | 0.35 ± 0.15 |
|
|
WBC: white blood cell; Lymph: lymphocyte; Mon: monocyte; Gran: granulocyte; RBC: red blood cell; HGB: hemoglobin; HCT: hematocrit; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin concentration; RDW: red blood cell distribution width; PLT: platelets; MPV: mean platelet volume; PDW: platelet distribution width; PCT: plateletcrit.
|
